why choose us

First received: June 15, 2023

Clinical Trial: Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Lymphoma, Primary Effusion

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma

Brief Summary: Background:Primary effusion lymphoma (PEL) is an aggressive form of cancer that affects cells in the immune system and lymph nodes.How PEL develops is not well understood, and this disease does not respond well to standard treatments for other types of lymphomas.Objective:To test a drug treatment (daratumumab SC) in people with PEL.Eligibility:People aged 18 and older with PEL.Their PEL must have failed to respond to therapy or they must be unable to receive standard treatment for the disease.Design:Participants…

Read more